Genea Biomedx and Rhea Fertility Sign MOU to Lead Innovation in Assisted Reproductive Technology
Genea Biomedx, part of Basecare Medical Group, has signed an MOU with Rhea Fertility to drive innovation in assisted reproductive technology. This partnership will leverage Genea Biomedx’s advanced lab automation solutions to optimise IVF processes in Rhea’s clinics worldwide. By integrating cutting-edge technology, Genea Biomedx continues to set new standards in efficiency, precision, and clinic
- (1888PressRelease) February 26, 2025 - Suzhou - Genea Biomedx part of Basecare Medical Group, a global leader in technology for assisted reproduction laboratories, and Rhea Fertility have signed a Memorandum of Understanding (MOU) today during an official ceremony at Basecare’s headquarters in China. The agreement marks the beginning of a strategic collaboration aimed at revolutionizing fertility treatment through cutting-edge innovation.
The signing ceremony was attended by senior executives from both companies, including Marian Garriga, CEO of Genea Biomedx, and Margaret Wang, CEO of Rhea Fertility.
“This collaboration with Rhea Fertility represents an exciting step toward the future of assisted reproduction. By combining our expertise in laboratory automation with Rhea’s advancements in AI and women’s health, we are setting the foundation for smarter, more efficient fertility treatments. Together, we aim to deliver tangible benefits to clinics and patients worldwide,” said Marian Garriga, CEO of Genea Biomedx.
"At Rhea Fertility our mission is to elevate reproductive health journeys for intent parents globally. We are dedicated to integrating AI and women’s health solutions to enhance fertility treatments. Our partnership with Genea Biomedx is a game-changer in automating and optimising IVF processes in our labs” said Margaret Wang, CEO of Rhea Fertility.
The partnership aims to drive innovation in Rhea’s IVF laboratories by leveraging Genea Biomedx technologies to automate processes and develop smart reproductive centers. It will integrate AI solutions to enhance laboratory workflows and improve clinical outcomes. Additionally, the collaboration will support Rhea’s global expansion, with a focus on key markets including the United States, Europe, South America, and Southeast Asia. As part of this strategic alliance, Rhea Fertility will gain early access to Genea Biomedx’s latest products and participate in its Beta Release Program, fostering product development and innovation.
Rhea Fertility brings its expertise in women’s health and AI-driven innovations, supported by its partnerships with NUS Singapore Lab and Baylor College of Medicine. This collaboration will enable the development of intelligent IVF clinics, enhancing the patient experience with more precise and efficient treatment options.
The ceremony concluded with both companies reaffirming their shared commitment to setting new benchmarks in assisted reproductive technology and creating smarter solutions for fertility clinics worldwide.
About Genea Biomedx
Genea Biomedx is a leading global provider and manufacturer of medical devices designed to simplify and automate the fertility treatment process, focusing on improving clinical outcomes. Genea Biomedx's team of experts is dedicated to reducing the impact of uncontrollable variables like human error and environmental factors through innovative technology that enhances industry standards. Our cutting-edge devices provide exceptional performance and reliability, ensuring optimal clinical outcomes. Our products increase efficiency and reduce errors with intuitive interfaces and automated features. We invest heavily in R&D to help revolutionize the IVF industry. Genea Biomedx is a trusted partner that provides exceptional customer service, training, and technical support to laboratories worldwide.
About Rhea Fertility
Rhea is a modern global reproductive health services company elevating fertility journeys for the modern family. The company’s clinical services are delivered by Rhea’s GenPrime clinic network and a growing number of partner clinics. The company’s clinic network is powered by Rhea Labs, an integrated technology platform leveraging the flywheel of accelerated time to market and short product feedback loop to improve patient outcomes. Incubated and developed by Recharge Capital, a leading thematic-first investment firm, Rhea is a Cayman entity headquartered in Singapore and New York, U.S., serving markets across Asia with additional operations in North America and Europe.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam